Florian Wittlinger

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Structural Basis

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Journal of medicinal chemistry

ACS medicinal chemistry letters

This page only lists publications with an associated author ORCID identifier.

Publications

Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, Ramona Rudalska, Guiqun Wang, Martin Peter Schwalm, Alexander Rasch, Benedikt Wagner, Stefan A Laufer, Stefan Knapp, Daniel Dauch, Alexander Titz
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S N Ar Electrophiles. Journal of medicinal chemistry (2024)
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, Ramona Rudalska, Guiqun Wang, Martin Peter Schwalm, Alexander Rasch, Benedikt Wagner, Stefan A Laufer, Stefan Knapp, Daniel Dauch, Alexander Titz
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S N Ar Electrophiles. Journal of medicinal chemistry 67 (8) (2024)
David E Heppner, Florian Wittlinger, Tyler S Beyett, Tatiana Shaurova, Daniel A Urul, Brian Buckley, Calvin D Pham, Ilse K Schaeffner, Bo Yang, Blessing C Ogboo, Earl W May, Erik M Schaefer, Michael J Eck, Stefan A Laufer, Pamela A Hershberger
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448). ACS medicinal chemistry letters 13 (12) (2022)
David E Heppner, Florian Wittlinger, Tyler S Beyett, Tatiana Shaurova, Daniel A Urul, Brian Buckley, Calvin D Pham, Ilse K Schaeffner, Bo Yang, Blessing C Ogboo, Earl W May, Erik M Schaefer, Michael J Eck, Stefan A Laufer, Pamela A Hershberger
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448). ACS medicinal chemistry letters 13 (12) (2022)
Florian Wittlinger, David E Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K Rana, Anna M Schmoker, Tyler S Beyett, Lena Marie Berger, Benedict-Tilmann Berger, Nicolas Bauer, James D Vasta, Cesear R Corona, Matthew B Robers, Stefan Knapp, Pasi A Jänne, Michael J Eck, Stefan A Laufer
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. Journal of medicinal chemistry (2021)